Skip to main content
SpringerLink
Log in

Bevacizumab not cost effective for HER2-negative mBC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2012 euros

Reference

  • van Kampen RJ, et al. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. European Journal of Cancer : 25 Feb 2017. Available from: URL: http://doi.org/10.1016/j.ejca.2017.01.027

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bevacizumab not cost effective for HER2-negative mBC. PharmacoEcon Outcomes News 773, 10 (2017). https://doi.org/10.1007/s40274-017-3795-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3795-0

Search

Navigation